[ad_1]
In a statement from BioNTech, BritainEngland to establish a research and development center for cancer treatment in Health It has been agreed with the Ministry.
In the statement, it was emphasized that by 2030, it is aimed to treat up to 10 thousand cancer patients in clinical trials with mRNA cancer immunotherapies.
R&D CENTER WILL BE OPENED
In the statement, it was stated that it is planned to include the first cancer patient in clinical trials in the second half of 2023, and it was reported that BioNTech will open an R&D center in Cambridge city of the country where more than 70 scientists will be employed.
BioNTech’s CEO and Co-Founder Prof. Dr. Uğur Şahin stated that the agreement reached with the UK is a result of the lessons learned from the Covid-19 pandemic, and said, “The cooperation will focus on the treatment of various types of cancer and infectious diseases that collectively affect hundreds of millions of people around the world.”
BioNTech, in a statement on December 23, 2022, reported that clinical trials of the malaria vaccine had begun with the mRNA technology used to produce the Covid-19 vaccine.
[ad_2]
